Nature Medicine

Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial

By Lixin Guo, Dongni Yu, Yimei Xu, Yuan Gao

Trial in peopleInterventions

The paper

Lixin Guo, Dongni Yu, Yimei Xu, Yuan Gao

Chinese Academy of Medical Sciences & Peking Union Medical College; Jingjiang People’s Hospital

Nature Medicine, 5 Oct 2026

doi.org/10.1038/s41591-026-04713-y PubMed 42834229

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial